

## Dehdashti, Seameen (Jean)

---

**From:** Dehdashti, Seameen (Jean)  
**Sent:** Thursday, November 01, 2018 3:19 PM  
**To:** 'BDV (Barbara Davies)'  
**Cc:** Dehdashti, Seameen (Jean)  
**Subject:** RE: BLA 12567/0: Sponsor Minutes of 1 Nov 2018 Teleconference  
**Attachments:** Slides for FDA telecon 01.nov.2018 (002).pptx

**Follow Up Flag:** Follow up  
**Flag Status:** Flagged

Dear Barbara,

Thank you for the provided summary of our teleconference today, November 1, 22018. Please see an additional bullet point that was added by Dr. Bhattacharyya and Dr. Dutt below. Please note that we are in agreement with the summary as captured below, and I will move forward with filing this information accordingly under BLA 125671/0.

### **Summary of FDA-Novo Nordisk Teleconference on November 1, 2018 RE: BLA 125671/0**

- **Agency agreed with Novo Nordisk's approach to use an (b) (4) method to demonstrate the accuracy of the chromogenic assay for Potency (please see attached slides).**
- **Agency suggested and Novo Nordisk agreed to use (b) (4) lots of (b) (4) and (b) (4) lots (different than reference standard) of drug product, in addition to the reference standard, in the one-stage and chromogenic assays for the accuracy study.**
- **Novo Nordisk commits to provide the requested data by November 26, 2018, and will submit earlier if possible.**
- **In view of the agreement between FDA and Novo Nordisk as discussed above, FDA agreed to withdraw the third item sent to Novo Nordisk, which is "Please provide clarification on your inability to conduct accuracy study by (b) (4) and measuring the potency by the chromogenic method."**

Please do not hesitate to contact me, should you have any questions and/or concerns.

Warm regards,

**Jean Dehdashti, MSc, RAC**  
**Regulatory Project Manager**

Center for Biologics and Evaluation  
Office of Tissues and Advanced Therapies  
U.S. Food and Drug Administration  
Tel: 240-402-9146  
[Seameen.Dehdashti@fda.hhs.gov](mailto:Seameen.Dehdashti@fda.hhs.gov)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

---

**From:** BDV (Barbara Davies) <bdv@novonordisk.com>  
**Sent:** Thursday, November 01, 2018 2:20 PM  
**To:** Dehdashti, Seameen (Jean) <Seameen.Dehdashti@fda.hhs.gov>  
**Subject:** BLA 12567/0: Sponsor Minutes of 1 Nov 2018 Teleconference

Dear Jean,

Here are the agreements we reached during the teleconference, and one update:

- Agency agreed with Novo Nordisk's approach to use an (b) (4) method to demonstrate the accuracy of the chromogenic assay for Potency
- Agency suggested and Novo Nordisk agreed to use (b) (4) lots of (b) (4) and (b) (4) lots (different than reference standard) of drug product, in addition to the reference standard, in the one-stage and chromogenic assays for the accuracy study
- Novo Nordisk commits to provide the requested data by November 26, and will submit earlier if possible

We thank you and Drs. Dutt and Bhattacharyya for the very useful call earlier today.

Best regards,  
Barbara

**Barbara Davies**  
Senior Manager  
Regulatory Affairs, CMR

**Novo Nordisk Inc.**  
800 Scudders Mill Road  
Plainsboro, NJ 08536  
+1 609-987-5800

1-609-786-4774  
1-609-651-9687 (mobile)  
bdv@novonordisk.com  
www.novonordisk-us.com



This e-mail (including any attachments) is intended for the addressee(s) stated above only and may contain confidential information protected by law. You are hereby notified that any unauthorized reading, disclosure, copying or distribution of this e-mail or use of information contained herein is strictly prohibited and may violate rights to proprietary information. If you are not an intended recipient, please return this e-mail to the sender and delete it immediately hereafter. Thank you.